Nxera Pharma Korea

Nxera Pharma Korea, a subsidiary of Nxera Pharma, has signed an exclusive supply and distribution agreement with Handok to commercialize PIVLAZ™ in South Korea. Under the terms of the agreement, Nxera Pharma Korea will supply the medication to Handok at an agreed price, and Handok will have exclusive responsibility for the promotion, marketing, sales, and distribution of PIVLAZ™ in South Korea. PIVLAZ™ is the first drug approved in South Korea for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH).